GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹457 Cr | ₹489 Cr | ₹90 Cr | ₹94 Cr | ₹80 Cr |
What is the latest Total Non-Current Liabilities ratio of GLAND PHARMA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹457 Cr |
| Mar2024 | ₹489 Cr |
| Mar2023 | ₹90 Cr |
| Mar2022 | ₹94 Cr |
| Mar2021 | ₹80 Cr |
How is Total Non-Current Liabilities of GLAND PHARMA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹457 Cr | -6.41 | |
| Mar2024 | ₹489 Cr | 444.83 | |
| Mar2023 | ₹90 Cr | -4.57 | |
| Mar2022 | ₹94 Cr | 17.01 | |
| Mar2021 | ₹80 Cr | - | |
Compare Total Non-Current Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹27,698.8 Cr | -1% | -1.8% | -8.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹415,073.0 Cr | -0% | -3.2% | -5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,657.0 Cr | 4% | 5.2% | 11.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹134,121.0 Cr | 2.4% | 4.5% | 18.3% | Stock Analytics | |
| CIPLA | ₹118,431.0 Cr | -3.5% | -1.5% | -2.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,944.0 Cr | -3.2% | -3.3% | -10.6% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | -1% |
-1.8% |
-8.2% |
| SENSEX | -2.6% |
-1.3% |
7.2% |
You may also like the below Video Courses